BioXcel Therapeutics (NASDAQ:BTAI) is a clinical-stage biopharmaceutical company that leverages artificial intelligence and machine learning to identify and develop novel therapies across neuroscience and immuno-oncology. The company’s proprietary BioXcel® platform aims to repurpose existing molecular entities for new indications, accelerating development timelines and reducing the risks associated with traditional drug discovery. Since its founding in 2015, BioXcel has focused on bringing innovative treatments to patients with significant unmet medical needs.
The company’s neuroscience pipeline is anchored by BXCL501, a sublingual thin-film formulation of dexmedetomidine being evaluated for the acute treatment of agitation in patients with schizophrenia and Alzheimer’s disease. BXCL501 has demonstrated rapid onset of action and a favorable safety profile in early clinical studies. In immuno-oncology, BioXcel is advancing BXCL701, an oral innate immunity activator designed to stimulate the immune system against certain solid tumors. BXCL701 has shown promise in combination with checkpoint inhibitors in prostate and pancreatic cancer models.
BioXcel’s AI-driven platform supports target identification, candidate selection and trial design, enabling a more efficient pathway from discovery to the clinic. By repurposing molecules that already have established safety data, the company is able to streamline regulatory processes and focus resources on clinical development. BioXcel also engages in strategic partnerships with academic institutions and biopharmaceutical collaborators to broaden its research capabilities and accelerate the progression of its lead programs.
Headquartered in Danbury, Connecticut, BioXcel Therapeutics operates primarily in the United States, with research collaborations and clinical trial sites spanning North America. Under the leadership of CEO Vus Latif, Ph.D., a biotechnology veteran with extensive experience in drug development, the company continues to build a multidisciplinary team encompassing clinical, regulatory and commercial expertise. BioXcel is committed to translating its innovative approach into effective therapies for patients worldwide.
